Tag Archive for PRO/EDR> Hepatitis B – USA (08): reactivation during hepatitis C therapy
PRO/EDR> Hepatitis B – USA (08): reactivation during hepatitis C therapy
Hepatitis B -- United StatesThe FDA is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral (DAA) medicines for hepatitis C virus. In a few cases, HBV reactivation in patients treated with DAA medicines resulted in serious liver problems or death.As a result, we are requiring a Boxed Warning, our most prominent warning, about the risk of HBV reactivation Read more [...]
